BRPI0309992B1 - método para purificar albumina de soro humano recombinante (rhsa) de uma solução - Google Patents
método para purificar albumina de soro humano recombinante (rhsa) de uma solução Download PDFInfo
- Publication number
- BRPI0309992B1 BRPI0309992B1 BRPI0309992-0A BR0309992A BRPI0309992B1 BR PI0309992 B1 BRPI0309992 B1 BR PI0309992B1 BR 0309992 A BR0309992 A BR 0309992A BR PI0309992 B1 BRPI0309992 B1 BR PI0309992B1
- Authority
- BR
- Brazil
- Prior art keywords
- matrix
- rhsa
- ccs
- hic
- cation exchange
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 54
- 108091006905 Human Serum Albumin Proteins 0.000 title claims abstract description 9
- 102000008100 Human Serum Albumin Human genes 0.000 title claims abstract description 9
- 239000011159 matrix material Substances 0.000 claims abstract description 60
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims abstract description 31
- 150000001768 cations Chemical class 0.000 claims abstract description 24
- 238000005341 cation exchange Methods 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 239000012228 culture supernatant Substances 0.000 claims abstract description 14
- 230000002902 bimodal effect Effects 0.000 claims abstract description 12
- 238000004113 cell culture Methods 0.000 claims abstract description 12
- 238000005349 anion exchange Methods 0.000 claims abstract description 8
- 239000003446 ligand Substances 0.000 claims description 47
- 230000003993 interaction Effects 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 230000002209 hydrophobic effect Effects 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 150000001450 anions Chemical class 0.000 claims description 8
- 238000011210 chromatographic step Methods 0.000 claims description 8
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 13
- 239000000243 solution Substances 0.000 abstract description 10
- 238000010790 dilution Methods 0.000 abstract description 3
- 239000012895 dilution Substances 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000012619 Butyl Sepharose® Substances 0.000 description 11
- 229920002684 Sepharose Polymers 0.000 description 11
- 229920000936 Agarose Polymers 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 125000005647 linker group Chemical group 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical class C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- -1 etc.) Chemical group 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229920002271 DEAE-Sepharose Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000005277 cation exchange chromatography Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 229910010272 inorganic material Inorganic materials 0.000 description 4
- 239000011147 inorganic material Substances 0.000 description 4
- 239000011368 organic material Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000002109 Argyria Diseases 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 241000235058 Komagataella pastoris Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 238000005571 anion exchange chromatography Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229910018828 PO3H2 Inorganic materials 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012504 chromatography matrix Substances 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229960005480 sodium caprylate Drugs 0.000 description 2
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- BPUBBGLMJRNUCC-UHFFFAOYSA-N oxygen(2-);tantalum(5+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Ta+5].[Ta+5] BPUBBGLMJRNUCC-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920002454 poly(glycidyl methacrylate) polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229910001936 tantalum oxide Inorganic materials 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201518A SE526227C2 (sv) | 2002-05-15 | 2002-05-15 | Metod för rening av rekombinant humant serumalbumin |
| SE0201518-8 | 2002-05-15 | ||
| PCT/SE2003/000766 WO2003097692A1 (en) | 2002-05-15 | 2003-05-09 | Method for albumin purification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR0309992A BR0309992A (pt) | 2005-03-01 |
| BRPI0309992B1 true BRPI0309992B1 (pt) | 2020-12-22 |
Family
ID=20287916
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0309992A BRPI0309992B8 (pt) | 2002-05-15 | 2003-05-09 | método para purificar albumina de soro humano recombinante (rhsa) de uma solução |
| BRPI0309992-0A BRPI0309992B1 (pt) | 2002-05-15 | 2003-05-09 | método para purificar albumina de soro humano recombinante (rhsa) de uma solução |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0309992A BRPI0309992B8 (pt) | 2002-05-15 | 2003-05-09 | método para purificar albumina de soro humano recombinante (rhsa) de uma solução |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7423124B2 (enExample) |
| EP (2) | EP1504031B1 (enExample) |
| JP (2) | JP2006502098A (enExample) |
| CN (1) | CN100463921C (enExample) |
| AT (1) | ATE335006T1 (enExample) |
| AU (2) | AU2003228193B2 (enExample) |
| BR (2) | BRPI0309992B8 (enExample) |
| CA (2) | CA2483612A1 (enExample) |
| DE (1) | DE60307262T2 (enExample) |
| ES (1) | ES2268362T3 (enExample) |
| IL (1) | IL164844A (enExample) |
| SE (1) | SE526227C2 (enExample) |
| WO (2) | WO2003097692A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802146B2 (en) * | 1998-11-06 | 2014-08-12 | Neomend, Inc. | Systems, methods, and compositions for prevention of tissue adhesion |
| PT1599463E (pt) * | 2003-01-28 | 2013-09-03 | Du Pont | Insecticidas à base de ciano-antranilamida |
| EP1608457A1 (en) * | 2003-03-12 | 2005-12-28 | Fresenius Kabi Deutschland GmbH | Use of recombinant albumin in dialysis after liver failure |
| AU2005235634B2 (en) * | 2004-04-23 | 2011-10-20 | Conjuchem Biotechnologies Inc. | Method for the purification of albumin conjugates |
| CN1854155B (zh) * | 2005-04-29 | 2010-11-17 | 华北制药集团新药研究开发有限责任公司 | 一种纯化rHSA的方法 |
| AR067537A1 (es) * | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Purificacion de polipeptidos pegilados |
| AR067536A1 (es) | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea |
| CN101978268B (zh) * | 2008-03-31 | 2014-04-23 | 积水医疗株式会社 | 纯化血清白蛋白及免疫学测定方法 |
| US8753868B2 (en) | 2008-08-04 | 2014-06-17 | General Electric Company | Method and system for selective isolation of target biological molecules in a general purpose system |
| CN101768206B (zh) * | 2008-12-31 | 2013-05-15 | 华北制药集团新药研究开发有限责任公司 | 一种重组人血清白蛋白的纯化方法及其应用 |
| CN102369276B (zh) | 2009-02-20 | 2015-02-04 | 文特里亚生物科学公司 | 含有蛋白质组合的细胞培养基 |
| SG10201710439UA (en) * | 2010-05-25 | 2018-01-30 | Genentech Inc | Methods of purifying polypeptides |
| CN102127164B (zh) | 2010-12-20 | 2013-01-30 | 武汉禾元生物科技有限公司 | 一种从水稻种子中提取重组人血清白蛋白的方法 |
| CN102532254B (zh) * | 2010-12-24 | 2015-06-24 | 武汉禾元生物科技股份有限公司 | 一种从水稻种子中分离纯化重组人血清白蛋白的方法 |
| WO2013134251A2 (en) * | 2012-03-08 | 2013-09-12 | Bio-Rad Laboratories, Inc. | Anionic exchange-hydrophobic mixed mode |
| CN103880947B (zh) | 2012-12-21 | 2016-01-13 | 武汉禾元生物科技股份有限公司 | 一种分离纯化高纯度重组人血清白蛋白的层析方法 |
| CN103923211A (zh) * | 2014-05-08 | 2014-07-16 | 齐智 | 一种医药级重组人血清白蛋白的纯化方法 |
| JP2018517415A (ja) | 2015-06-10 | 2018-07-05 | ナントクエスト インコーポレイテッド | がんを処置するための改変ｎｋ−９２細胞 |
| CN106117347A (zh) * | 2015-12-09 | 2016-11-16 | 烟台大学 | 一种疏水层析制备高纯度藻红蛋白的方法 |
| CN106117326A (zh) * | 2015-12-09 | 2016-11-16 | 烟台大学 | 一种离心法结合阴离子交换层析介质制备藻红蛋白的方法 |
| CN106146631A (zh) * | 2015-12-09 | 2016-11-23 | 烟台大学 | 一种离心技术结合疏水层析介质制备藻红蛋白的方法 |
| KR20220066393A (ko) | 2019-09-24 | 2022-05-24 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법 |
| US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
| US12161777B2 (en) | 2020-07-02 | 2024-12-10 | Davol Inc. | Flowable hemostatic suspension |
| US20230331772A1 (en) | 2020-12-08 | 2023-10-19 | Tonghua Anrate Biopharmaceutical Co., Ltd | Method for purification of recombinant proteins |
| CN116744984A (zh) | 2020-12-28 | 2023-09-12 | 达沃有限公司 | 包含蛋白质和多官能化改性的基于聚乙二醇的交联剂的反应性干粉状止血材料 |
| CN113461804A (zh) * | 2021-08-09 | 2021-10-01 | 山东健通生物科技有限公司 | 减少重组人血白蛋白发酵过程中色素的方法 |
| CN113880908B (zh) * | 2021-08-25 | 2024-05-14 | 北京伟德杰生物科技有限公司 | 纯化重组人血清白蛋白的融合蛋白的方法 |
| CN113735962B (zh) * | 2021-08-27 | 2023-11-10 | 常熟纳微生物科技有限公司 | 一种从猪血中纯化重组人血清白蛋白的方法及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4093612A (en) | 1975-08-04 | 1978-06-06 | Research Corporation | Selective removal of albumin from blood fluids and compositions therefore |
| FR2403098A1 (fr) | 1977-09-19 | 1979-04-13 | Merieux Inst | Nouveau materiau capable de fixer de facon reversible des macromolecules biologiques, sa preparation et son application |
| US5849874A (en) * | 1991-07-12 | 1998-12-15 | Gist-Brocades, N.V. | Process for the purification of serum albumin |
| IE20000781A1 (en) * | 1991-07-12 | 2001-02-21 | Dsm Nv | Process for the purification of serum albumin |
| US5440018A (en) * | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
| US5521287A (en) * | 1992-05-20 | 1996-05-28 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
| JPH07102148B2 (ja) * | 1992-05-20 | 1995-11-08 | 株式会社ミドリ十字 | 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物 |
| CA2116385A1 (en) * | 1993-02-25 | 1994-08-26 | Akinori Sumi | Human serum albumin and process for producing the same |
| DK0658569T3 (da) | 1993-12-17 | 2005-02-07 | Mitsubishi Pharma Corp | Fremgangsmåde til affarvning af humant serumalbumin |
| DK0699687T3 (da) | 1994-08-31 | 2004-04-26 | Mitsubishi Pharma Corp | Fremgangsmåde til oprensning af rekombinant humant serumalbumin |
| JP3840674B2 (ja) * | 1994-08-31 | 2006-11-01 | 三菱ウェルファーマ株式会社 | 遺伝子操作に由来するヒト血清アルブミンの精製方法 |
| GB9902000D0 (en) * | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
| SE0002688D0 (sv) * | 2000-07-17 | 2000-07-17 | Amersham Pharm Biotech Ab | Adsorption method and ligands |
| JP4798832B2 (ja) * | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | ヒト血清アルブミン多量体の除去方法 |
-
2002
- 2002-05-15 SE SE0201518A patent/SE526227C2/sv not_active IP Right Cessation
-
2003
- 2003-05-09 CA CA002483612A patent/CA2483612A1/en not_active Abandoned
- 2003-05-09 WO PCT/SE2003/000766 patent/WO2003097692A1/en not_active Ceased
- 2003-05-09 AT AT03725953T patent/ATE335006T1/de not_active IP Right Cessation
- 2003-05-09 EP EP03725953A patent/EP1504031B1/en not_active Expired - Lifetime
- 2003-05-09 ES ES03725953T patent/ES2268362T3/es not_active Expired - Lifetime
- 2003-05-09 DE DE60307262T patent/DE60307262T2/de not_active Expired - Lifetime
- 2003-05-09 BR BRPI0309992A patent/BRPI0309992B8/pt active IP Right Grant
- 2003-05-09 JP JP2004506364A patent/JP2006502098A/ja active Pending
- 2003-05-09 AU AU2003228193A patent/AU2003228193B2/en not_active Ceased
- 2003-05-09 CN CNB031235026A patent/CN100463921C/zh not_active Expired - Fee Related
- 2003-05-09 US US10/514,536 patent/US7423124B2/en not_active Expired - Lifetime
- 2003-05-09 BR BRPI0309992-0A patent/BRPI0309992B1/pt active IP Right Grant
- 2003-05-15 AU AU2003232704A patent/AU2003232704A1/en not_active Abandoned
- 2003-05-15 WO PCT/SE2003/000792 patent/WO2003097693A1/en not_active Ceased
- 2003-05-15 US US10/514,544 patent/US7351801B2/en not_active Expired - Fee Related
- 2003-05-15 JP JP2004506365A patent/JP4559216B2/ja not_active Expired - Fee Related
- 2003-05-15 CA CA002483616A patent/CA2483616A1/en not_active Abandoned
- 2003-05-15 EP EP03752962A patent/EP1504032A1/en not_active Withdrawn
-
2004
- 2004-10-26 IL IL164844A patent/IL164844A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20050214902A1 (en) | 2005-09-29 |
| JP2006512283A (ja) | 2006-04-13 |
| CA2483616A1 (en) | 2003-11-27 |
| CN100463921C (zh) | 2009-02-25 |
| US7351801B2 (en) | 2008-04-01 |
| AU2003228193B2 (en) | 2009-05-07 |
| SE0201518D0 (sv) | 2002-05-15 |
| WO2003097692A1 (en) | 2003-11-27 |
| IL164844A (en) | 2009-09-01 |
| IL164844A0 (en) | 2005-12-18 |
| JP2006502098A (ja) | 2006-01-19 |
| ATE335006T1 (de) | 2006-08-15 |
| EP1504031A1 (en) | 2005-02-09 |
| AU2003232704A1 (en) | 2003-12-02 |
| EP1504032A1 (en) | 2005-02-09 |
| EP1504031B1 (en) | 2006-08-02 |
| CA2483612A1 (en) | 2003-11-27 |
| WO2003097693A1 (en) | 2003-11-27 |
| JP4559216B2 (ja) | 2010-10-06 |
| CN1496993A (zh) | 2004-05-19 |
| BRPI0309992B8 (pt) | 2023-03-21 |
| US20050215765A1 (en) | 2005-09-29 |
| SE526227C2 (sv) | 2005-08-02 |
| ES2268362T3 (es) | 2007-03-16 |
| AU2003228193A1 (en) | 2003-12-02 |
| US7423124B2 (en) | 2008-09-09 |
| BR0309992A (pt) | 2005-03-01 |
| DE60307262D1 (de) | 2006-09-14 |
| DE60307262T2 (de) | 2007-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0309992B1 (pt) | método para purificar albumina de soro humano recombinante (rhsa) de uma solução | |
| KR100771252B1 (ko) | 양이온 교환 크로마토그래피를 통한 약리학적 활성단백질의 정제방법 | |
| KR100839937B1 (ko) | 가열처리 공정을 포함하는 인체 혈청알부민의 제조방법 | |
| KR100847883B1 (ko) | 인체 혈청알부민 다량체의 제거방법 | |
| RS60210B1 (sr) | Novi postupak za efikasno prečišćavanje humanog albumina iz seruma | |
| CN116874571A (zh) | 突变的蛋白a结构域c及其应用 | |
| CN109535248B (zh) | 洗涤缓冲液及采用该洗涤缓冲液提纯牛血红蛋白的方法 | |
| JPH08116985A (ja) | 遺伝子操作に由来するヒト血清アルブミンの精製方法 | |
| CN110770251A (zh) | 纯化白蛋白融合蛋白的方法 | |
| Mizutani | Adsorption chromatography of biopolymers on porous glass | |
| CN118742559A (zh) | 蛋白a的b结构域和z结构域突变体及其应用 | |
| KR20050016877A (ko) | 알부민 정제 방법 | |
| JP4016999B2 (ja) | 遺伝子操作に由来するヒト血清アルブミンの精製方法 | |
| HK1055596A (en) | Method of eliminating human serum albumin polymers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/05/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25D | Requested change of name of applicant approved |
Owner name: NORTH CHINA PHARMACEUTICAL GROUP CORPORATION (CN) ; CYTIVA SWEDEN AB (SE) |